
Eyenovia EYEN
Quarterly report 2025-Q2
added 08-13-2025
Eyenovia Cost of Revenue 2011-2026 | EYEN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Eyenovia
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.93 M | 16 K | - | 1.6 M | 800 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.93 M | 16 K | 1.59 M |
Quarterly Cost of Revenue Eyenovia
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 48 | - | 133 K | 490 K | 203 K | - | 13.4 K | - | - | - | - | - | - | - | - | 800 K | 800 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 800 K | 48 | 348 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
421 K | $ 0.88 | -1.69 % | $ 6.47 M | ||
|
Aquestive Therapeutics
AQST
|
18.6 M | $ 4.1 | - | $ 438 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 9.59 | - | $ 620 M | ||
|
I-Mab
IMAB
|
27.2 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
81.8 M | $ 22.45 | - | $ 3.72 B | ||
|
Cerus Corporation
CERS
|
33.4 M | $ 2.03 | - | $ 387 M | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
12.4 B | - | - | $ 96.9 B | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Caladrius Biosciences
CLBS
|
31.1 M | - | -16.75 % | $ 25.8 M | ||
|
Aeterna Zentaris
AEZS
|
90 K | - | 5.93 % | $ 314 M | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 103.45 | - | $ 27.2 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.73 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
145 M | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
49.4 M | - | - | $ 2.02 B | ||
|
Evogene Ltd.
EVGN
|
767 K | $ 0.78 | - | $ 27.9 M | ||
|
Edesa Biotech
EDSA
|
17.6 K | $ 18.27 | - | $ 58.4 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
24 K | - | -9.21 % | $ 2.55 M | ||
|
CureVac N.V.
CVAC
|
238 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K |